-
公开(公告)号：US06440656B1
公开(公告)日：2002-08-27
申请号：US08255208
申请日：1994-06-07
申请人： Dani Paul Bolognesi , Thomas James Matthews , Carl T. Wild , Shawn O'Lin Barney , Dennis Michael Lambert , Stephen Robert Petteway, Jr.
发明人： Dani Paul Bolognesi , Thomas James Matthews , Carl T. Wild , Shawn O'Lin Barney , Dennis Michael Lambert , Stephen Robert Petteway, Jr.
IPC分类号： C12Q170
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/525 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0815 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/21 , C07K14/22 , C07K14/285 , C07K14/31 , C12N2710/16222 , C12N2730/10122 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , Y10S435/974 , Y10S530/826
摘要： Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI5, 107×178×4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-178, these peptides should provide a novel approach to the development of targeted therapies for the treatment of RSV infections.
摘要翻译： 病毒包膜或感染细胞膜与未感染细胞膜的融合是病毒生命周期中必不可少的一步。 最近涉及人类免疫缺陷病毒1型（HIV-1）的研究表明，衍生自跨膜（TM）蛋白gp41的潜在螺旋区域的合成肽（称为DP-107和DP-178）是病毒融合的有效抑制剂， 感染。 采用在其他病毒蛋白中检测相关结构基序（例如，ALLMOTI5,107x178x4和PLZIP）的计算机化抗病毒检索技术（C.A.S.T.）来鉴定呼吸道合胞病毒（RSV）中的相似区域。 在RSV基因组中鉴定了预测形成具有抗病毒活性的卷曲螺旋结构的几个保守的七肽重复结构域。 制备衍生自这些区域的16至39个氨基酸的合成肽，并在合适的体外筛选测定中评估其抗病毒活性。 这些肽被证明是RSV融合的有效抑制剂。 基于它们与已知的HIV-1抑制剂DP-107和DP-178的结构和功能等同性，这些肽应提供开发用于治疗RSV感染的靶向治疗的新方法。
-
2.发明授权Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission 失效用于抑制膜融合相关事件的组合物，包括流感病毒传播
公开(公告)号：US6060065A
公开(公告)日：2000-05-09
申请号：US475668
申请日：1995-06-07
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/215 , A61K39/245 , A61K39/29 , A61P31/12 , A61P31/16 , A61P31/18 , C07K5/083 , C07K5/087 , C07K5/09 , C07K5/093 , C07K5/103 , C07K5/107 , C07K5/113 , C07K5/117 , C07K7/04 , C07K14/005 , C07K14/02 , C07K14/025 , C07K14/05 , C07K14/11 , C07K14/115 , C07K14/12 , C07K14/125 , C07K14/13 , C07K14/135 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C12N9/94 , C12N9/96 , C12N9/98 , C12N9/99 , G01N33/50
CPC分类号： C07K14/005 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C12N7/00 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , A61K38/00 , A61K39/00 , C07K2319/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , Y10S530/826
摘要： The present invention relates to viral peptides referred to as "DP107- and DP178-like" peptides. Specifically, the invention relates to isolated influenza A DP107- and DP178-like peptides which are identified by sequence search motif algorithms. The peptides of the invention exhibit antiviral activity believed to result from inhibition of viral induced fusogenic events.
摘要翻译： 本发明涉及被称为“DP107-和DP178样”肽的病毒肽。 具体地，本发明涉及通过序列搜索基序算法鉴定的分离的流感A DP107-和DP178样肽。 本发明的肽显示抗病毒活性，被认为是由病毒诱导的融合事件的抑制引起的。
-
3.发明授权Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains 失效衍生自含有融合抑制结构域的1型和2型人类免疫缺陷病毒的分离肽公开(公告)号：US07794725B1
公开(公告)日：2010-09-14
申请号：US08484223
申请日：1995-06-07
IPC分类号： A61K39/21
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K2319/00 , C12N7/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译： 本发明涉及显示出有力的抗逆转录病毒活性的肽。 本发明的肽包含对应于HIV-1LAI gp41蛋白的氨基酸638至673的DP178（SEQ ID NO：1）肽以及DP178的片段，类似物和同系物。 本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。
-
4.发明授权Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission 失效使用能够消除病毒融合和传播的抗病毒肽抑制爱泼斯坦 - 巴尔病毒传播的方法公开(公告)号：US06518013B1
公开(公告)日：2003-02-11
申请号：US08485546
申请日：1995-06-07
IPC分类号： C12Q170
CPC分类号： C07K5/0806 , A61K38/00 , A61K39/00 , A61K2039/525 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/005 , C07K14/21 , C07K14/22 , C07K14/285 , C07K14/31 , C07K2319/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/15022 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722
摘要： Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1(HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI 5, 107×178×4, and PLZIP) in other viral proteins was employed to identify similar regions in the Epstein-Barr virus (EBV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the EBV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of EBV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-178, these peptides should provide a novel approach to the development of targeted therapies for the treatment of EBV infections.
摘要翻译： 病毒包膜或感染细胞膜与未感染细胞膜的融合是病毒生命周期中必不可少的一步。 最近涉及人类免疫缺陷病毒1型（HIV-1）的研究表明，衍生自跨膜（TM）蛋白gp41的潜在螺旋区域的合成肽（称为DP-107和DP-178）是病毒融合的有效抑制剂， 感染。 采用在其他病毒蛋白中检测相关结构基序（例如ALLMOTI 5,107x178x4和PLZIP）的计算机化抗病毒检索技术（C.A.S.T.）来鉴定爱泼斯坦 - 巴尔病毒（EBV）中的相似区域。 在EBV基因组中鉴定了预测形成具有抗病毒活性的卷曲螺旋结构的几个保守的七肽重复结构域。 制备衍生自这些区域的16至39个氨基酸的合成肽，并在合适的体外筛选测定中评估其抗病毒活性。 这些肽被证明是EBV融合的有效抑制剂。 基于它们与已知HIV-1抑制剂DP-107和DP-178的结构和功能等同性，这些肽应提供用于开发用于治疗EBV感染的靶向治疗的新方法。
-
5.发明授权Methods for inhibition of membrane fusion-associated events, including influenza virus 失效抑制膜融合相关事件的方法，包括流感病毒
公开(公告)号：US6068973A
公开(公告)日：2000-05-30
申请号：US485551
申请日：1995-06-07
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/215 , A61K39/245 , A61K39/29 , A61P31/12 , A61P31/16 , A61P31/18 , C07K5/083 , C07K5/087 , C07K5/09 , C07K5/093 , C07K5/103 , C07K5/107 , C07K5/113 , C07K5/117 , C07K7/04 , C07K14/005 , C07K14/02 , C07K14/025 , C07K14/05 , C07K14/11 , C07K14/115 , C07K14/12 , C07K14/125 , C07K14/13 , C07K14/135 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C12N9/94 , C12N9/96 , C12N9/98 , C12N9/99 , G01N33/50 , C12Q1/70 , A61K39/42 , C07K16/00
CPC分类号： C07K14/005 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C12N7/00 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , A61K38/00 , A61K39/00 , C07K2319/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译： 本发明涉及显示出有力的抗逆转录病毒活性的肽。 本发明的肽包含对应于HIV-1LAI gp41蛋白的氨基酸638至673的DP178（SEQ ID：1）肽，以及DP178的片段，类似物和同系物。 本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。
-
6.发明授权Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids 失效包含DP-178和用于治疗辅助剂的其它病毒融合抑制剂肽的融合蛋白公开(公告)号：US07122190B2
公开(公告)日：2006-10-17
申请号：US10267748
申请日：2002-10-09
申请人： Dani Paul Bolognesi , Thomas James Matthews , Carl T. Wild , Shawn O'Lin Barney , Dennis Michael Lambert , Stephen Robert Petteway , Alphonse J. Langlois
发明人： Dani Paul Bolognesi , Thomas James Matthews , Carl T. Wild , Shawn O'Lin Barney , Dennis Michael Lambert , Stephen Robert Petteway , Alphonse J. Langlois
IPC分类号： A61K39/21
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K2319/00 , C12N7/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译： 本发明涉及显示出有力的抗逆转录病毒活性的肽。 本发明的肽包含对应于HIV-1细胞gp41蛋白的氨基酸638至673的DP178（SEQ ID：1）肽以及DP178的片段，类似物和同系物。 本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。
-
7.发明授权Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains 失效衍生自含有融合抑制结构域的爱泼斯坦 - 巴尔病毒的分离的肽
公开(公告)号：US6093794A
公开(公告)日：2000-07-25
申请号：US471913
申请日：1995-06-07
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/215 , A61K39/245 , A61K39/29 , A61P31/12 , A61P31/16 , A61P31/18 , C07K5/083 , C07K5/087 , C07K5/09 , C07K5/093 , C07K5/103 , C07K5/107 , C07K5/113 , C07K5/117 , C07K7/04 , C07K14/005 , C07K14/02 , C07K14/025 , C07K14/05 , C07K14/11 , C07K14/115 , C07K14/12 , C07K14/125 , C07K14/13 , C07K14/135 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C12N9/94 , C12N9/96 , C12N9/98 , C12N9/99 , G01N33/50
CPC分类号： C07K14/005 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C12N7/00 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , A61K38/00 , A61K39/00 , C07K2319/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译： 本发明涉及显示出有力的抗逆转录病毒活性的肽。 本发明的肽包含对应于HIV-1LAI gp41蛋白的氨基酸638至673的DP178（SEQ ID：1）肽，以及DP178的片段，类似物和同系物。 本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。
-
8.发明授权Simian immunodeficiency virus peptides with antifusogenic and antiviral activities 失效具有抗融合和抗病毒活性的猿猴免疫缺陷病毒肽
公开(公告)号：US6017536A
公开(公告)日：2000-01-25
申请号：US360107
申请日：1994-12-20
IPC分类号： A61K38/00 , A61K39/00 , A61P31/18 , C07K5/083 , C07K5/087 , C07K5/09 , C07K5/093 , C07K5/103 , C07K5/107 , C07K5/113 , C07K5/117 , C07K14/02 , C07K14/05 , C07K14/11 , C07K14/115 , C07K14/12 , C07K14/125 , C07K14/13 , C07K14/135 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/21 , C07K14/22 , C07K14/285 , C07K14/31 , A61K39/21
CPC分类号： C07K5/0806 , C07K14/005 , C07K14/21 , C07K14/22 , C07K14/285 , C07K14/31 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , A61K2039/525 , A61K38/00 , A61K39/00 , C07K2319/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/15022 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722
摘要： The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107.times.178.times.4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
摘要翻译： 本发明涉及展现抗融合和抗病毒活性的肽。 本发明的肽由猿猴免疫缺陷病毒（SIV）蛋白质的16至39个氨基酸区域组成。 通过能够识别ALLMOTI5,107x178x4或PLZIP氨基酸图案的计算机算法鉴定这些区域。 这些基序与要求保护的肽的抗融合和抗病毒活性相关。
-
9.发明授权Compositions for inhibition of membrane fusion-associated events, including human parainfluenza virus transmission 失效用于抑制膜融合相关事件的组合物，包括人副流感病毒传播公开(公告)号：US06333395B1
公开(公告)日：2001-12-25
申请号：US08474349
申请日：1995-06-07
IPC分类号： C12N14115
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K2319/00 , C12N7/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译： 本发明涉及显示出有力的抗逆转录病毒活性的肽。 本发明的肽包含对应于HIV-1LAI gp41蛋白的氨基酸638至673的DP178（SEQ ID NO：1）肽以及DP178的片段，类似物和同系物。 本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。
-
10.发明授权
公开(公告)号：US6054265A
公开(公告)日：2000-04-25
申请号：US919597
申请日：1997-09-26
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/215 , A61K39/245 , A61K39/29 , A61P31/12 , A61P31/16 , A61P31/18 , C07K5/083 , C07K5/087 , C07K5/09 , C07K5/093 , C07K5/103 , C07K5/107 , C07K5/113 , C07K5/117 , C07K7/04 , C07K14/005 , C07K14/02 , C07K14/025 , C07K14/05 , C07K14/11 , C07K14/115 , C07K14/12 , C07K14/125 , C07K14/13 , C07K14/135 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C12N9/94 , C12N9/96 , C12N9/98 , C12N9/99 , G01N33/50 , C12Q1/70
CPC分类号： C07K14/005 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C12N7/00 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , A61K38/00 , A61K39/00 , C07K2319/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译： 本发明涉及显示出有力的抗逆转录病毒活性的肽。 本发明的肽包含对应于HIV-1LAI gp41蛋白的氨基酸638至673的DP178（SEQ ID：1）肽，以及DP178的片段，类似物和同系物。 本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.091 秒)
